Top Markets
Coin of the day
CTI BioPharma Corp. CTI BioPharma Corp.

CTI BioPharma Corp.

CTIC
株式のランク #12604
CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery,... CTI BioPharma Corp. is a biopharmaceutical company dedicated to the discovery, advancement, and commercialization of innovative, targeted treatments for blood cancers within the United States. Its key product is VONJO (pacritinib), an oral kinase inhibitor currently under investigation, specifically designed to target JAK2, FLT3, IRAK1, and CSF1R for the management of adult patients with myelofibrosis. The company holds licensing and collaboration agreements with Teva Pharmaceutical Industries Ltd., SBIO Pte Ltd., and Baxalta. Established in 1991 and based in Seattle, Washington, CTI BioPharma Corp. was previously known as Cell Therapeutics, Inc., adopting its current name in May 2014.
株価
$9.09
最終同期: 2023-06-23
時価総額
$567.77M
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 CTI BioPharma Corp. (CTIC)

カテゴリー

CTI BioPharma Corp.(CTIC)の配当利回りの履歴
CTI BioPharma Corp.(銘柄コード: CTIC)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
CTI BioPharma Corp.(CTIC)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)